Company intelligence

TriGemX Bio

BiotechSee connections →

Recent changes

  1. Oct 11, 2026Raised $94M Pulse 2.0
  2. Oct 11, 2026New investor: TCGX Pulse 2.0
  3. Oct 11, 2026TriGemX Bio Raises $94M For Migraine Drug Pulse story

Funding History

1 event · sources dated per row
DateEventAmountValuationInvestorsSource
Oct 11, 2026funding round$94M—
TCGXLeadunverifiedColumn Group
Pulse story

Investors

TCGX

Latest Pulse

  1. TriGemX Bio Raises $94M For Migraine DrugTriGemX Bio, formerly Kallyope, raised $94 million co-led by The Column Group, TCGX and Viking Global to push its migraine drug elismetrep through Phase 3.→

Coverage Timeline

newest first
  1. Oct 11, 2026FUNDINGTriGemX Bio Raises $94M For Migraine Drug$94M→

All Coverage

FUNDING

TriGemX Bio Raises $94M For Migraine Drug

Illustration for: TriGemX Bio Raises $94M For Migraine Drug
FUNDING$94M

TriGemX Bio Raises $94M For Migraine Drug

TriGemX Bio, formerly Kallyope, raised $94 million co-led by The Column Group, TCGX and Viking Global to push its migraine drug elismetrep through Phase 3.

DEEP DIVE

Related Companies

Same sector
Scribe TherapeuticsAttovia TherapeuticsApnimedRetension PharmaceuticalsBraveheart BioEli Lilly

TriGemX Bio FAQ

Who are TriGemX Bio's investors?

TriGemX Bio's investors include TCGX.

Sources & methodologyshow
Where these figures come from

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction